Disease workspace
Breast Cancer
Malignant neoplasm of breast tissue with heterogeneous molecular subtypes.
Unmet need
Prevention strategies in high-risk populations; adjuvant repurposing candidates.
Evidence behind this
Observational studies suggest reduced cancer incidence; RCTs in adjuvant setting show mixed results.
Mechanism
AMPK activation suppresses mTOR-mediated proliferation in breast epithelial cells.
Authoritative sources
AI-generated summary
Metformin shows mechanistic plausibility and epidemiological support for breast cancer risk reduction, but prospective RCT evidence in treatment-naïve adjuvant settings remains inconclusive. Suitable for hypothesis generation and trial design, not clinical recommendation outside diabetes care.
- Decensi A et al., 2012
- Coleman CB et al., 2013
This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.